-+ 0.00%
-+ 0.00%
-+ 0.00%

Aligos says partner Amoytop doses first participant in Phase 1 trial of HBV drug ALG-170675 in China

PUBT·08/12/2026 20:11:44
Listen to the news
Aligos says partner Amoytop doses first participant in Phase 1 trial of HBV drug ALG-170675 in China
  • Aligos Therapeutics began dosing in a Phase 1 trial of ALG-170675, an investigational antisense drug for chronic hepatitis B functional cure.
  • No clinical results were reported; initial readouts will come later as the study evaluates safety, tolerability, pharmacokinetics, pharmacodynamics.
  • Trial in China is run by partner Amoytop, which holds Greater China rights; single-ascending, multiple-ascending dosing planned in healthy volunteers.
  • Move into chronic HBV patients is planned for Q4 2026, positioning the program for potential combination regimens in the region.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808965) on August 12, 2026, and is solely responsible for the information contained therein.